Our Approach
Overcoming barriers for systemic delivery
Therapeutic viruses have huge potential yet cannot currently be delivered intravenously, being limited to intratumoral injection. This restricts their clinical use.
Our pioneering platform is designed to relieve this crucial barrier that prevents systemic delivery. This allows our cancer-killing virus to deliver medicinal payloads within the tumour to stimulate and reprogram the immune system to attack and destroy cancer.